Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.910
Neutral
RSI(14)
68.351
Neutral
STOCH(KDJ)(9,3,3)
50.482
Sell
ATR(14)
8.127
High Vlolatility
CCI(14)
48.310
Neutral
Williams %R
21.745
Buy
TRIX(12,20)
0.745
Sell
StochRSI(14)
36.759
Buy
Krystal Biotech Inc
KRYS240.800USD
+7.430+3.18%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
6.98BMarket Cap
34.91P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Krystal Biotech Inc
Currency: USD Updated: 2025-12-19Key Insights
Krystal Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 2/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 222.45.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Krystal Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
222.455
Target Price
-4.95%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Krystal Biotech Inc Highlights
StrengthsRisks
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Fairly Valued
The company’s latest PE is 34.91, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.05M shares, decreasing 5.37% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 90.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Krystal Biotech Inc is 9.09, ranking 21/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 97.80M, representing a year-over-year increase of 16.65%, while its net profit experienced a year-over-year increase of 192.00%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.70
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.77
Krystal Biotech Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Krystal Biotech Inc is 5.31, ranking 393/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is 34.91, which is 1176.16% below the recent high of 445.49 and 415.93% above the recent low of -110.29.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 2/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Krystal Biotech Inc is 8.50, ranking 105/404 in the Biotechnology & Medical Research industry. The average price target for Krystal Biotech Inc is 218.00, with a high of 255.00 and a low of 198.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
222.455
Target Price
-4.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Krystal Biotech Inc
KRYS
12
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Krystal Biotech Inc is 9.44, ranking 18/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 258.48 and the support level at 213.24, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
238.300
Buy
MA10
239.134
Buy
MA20
228.782
Buy
MA50
208.631
Buy
MA100
181.869
Buy
MA200
167.734
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Krystal Biotech Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.74%, representing a quarter-over-quarter decrease of 14.21%. The largest institutional shareholder is The Vanguard, holding a total of 2.79M shares, representing 9.61% of shares outstanding, with 1.51% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
Avoro Capital Advisors LLC
Krishnan (Krish S)
Krishnan (Suma M)
State Street Investment Management (US)
Soleus Capital Management, L.P.
Capital World Investors
Frazier Life Sciences Management, L.P.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Krystal Biotech Inc is 7.60, ranking 13/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.46
VaR
+4.83%
240-Day Maximum Drawdown
+36.56%
240-Day Volatility
+47.12%
Return
Best Daily Return
60 days
+5.48%
120 days
+8.37%
5 years
+121.65%
Worst Daily Return
60 days
-3.86%
120 days
-14.04%
5 years
-19.55%
Sharpe Ratio
60 days
+5.37
120 days
+3.17
5 years
+0.58
Risk Assessment
Maximum Drawdown
240 days
+36.56%
3 years
+42.26%
5 years
+51.93%
Return-to-Drawdown Ratio
240 days
+1.49
3 years
+1.57
5 years
+0.73
Skewness
240 days
-0.62
3 years
+2.91
5 years
+13.01
Volatility
Realised Volatility
240 days
+47.12%
5 years
+66.93%
Standardised True Range
240 days
+2.79%
5 years
+2.18%
Downside Risk-Adjusted Return
120 days
+381.46%
240 days
+381.46%
Maximum Daily Upside Volatility
60 days
+26.77%
Maximum Daily Downside Volatility
60 days
+21.07%
Liquidity
Average Turnover Rate
60 days
+1.24%
120 days
+1.22%
5 years
--
Turnover Deviation
20 days
+23.47%
60 days
+9.98%
120 days
+7.88%
Peer Comparison
Biotechnology & Medical Research
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Septerna Inc
SEPN
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Krystal Biotech Inc?
The TradingKey Stock Score provides a comprehensive assessment of Krystal Biotech Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Krystal Biotech Inc’s performance and outlook.
How do we generate the financial health score of Krystal Biotech Inc?
To generate the financial health score of Krystal Biotech Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Krystal Biotech Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Krystal Biotech Inc.
How do we generate the company valuation score of Krystal Biotech Inc?
To generate the company valuation score of Krystal Biotech Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Krystal Biotech Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Krystal Biotech Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Krystal Biotech Inc.
How do we generate the earnings forecast score of Krystal Biotech Inc?
To calculate the earnings forecast score of Krystal Biotech Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Krystal Biotech Inc’s future.
How do we generate the price momentum score of Krystal Biotech Inc?
When generating the price momentum score for Krystal Biotech Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Krystal Biotech Inc’s prices. A higher score indicates a more stable short-term price trend for Krystal Biotech Inc.
How do we generate the institutional confidence score of Krystal Biotech Inc?
To generate the institutional confidence score of Krystal Biotech Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Krystal Biotech Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Krystal Biotech Inc.
How do we generate the risk management score of Krystal Biotech Inc?
To assess the risk management score of Krystal Biotech Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Krystal Biotech Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Krystal Biotech Inc.
